Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610609 · ClinicalTrials.gov registry record · NA
Reducing Disparities in Primary Prevention of Cardiovascular Disease
A NA study of Cardiovascular Diseases and Cholesterol, LDL, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 646
- Enrollment target
- 3
- Study locations
NCT01610609 is a NA study of Cardiovascular Diseases and Cholesterol, LDL that has completed, run by Northwestern University. The registered enrollment target is 646 participants, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01610609, a NA study of Cardiovascular Diseases and Cholesterol, LDL, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 646 participants
- Enrollment target
- 3
- Study locations
Study Summary
Cardiovascular disease (CVD) is the leading cause of disparities in years of life lost by race and low socioeconomic status. Statins have been shown to decrease the risk of cardiovascular events among individuals with high CVD risk. Yet, despite increased statin use and overall declining CVD rates, disparities in statin use and disparities in the control of high cholesterol by race, ethnicity, and socioeconomic status have persisted. Objective: To improve the appropriate use of statins for primary cardiovascular disease prevention among high risk individuals at community health centers through a system of population health management that uses electronic health record (EHR) data to identify patients for targeted education and outreach. Aim 1: Conduct a randomized controlled trial among individuals with 10-year risk for myocardial infarction or coronary death of 10% or higher to determine if the population health management intervention, compared to usual care, results in higher rates of documented statin treatment discussions within 6 months (primary process outcome), higher rates of statin prescribing within 6 months (secondary process outcome), and higher rates of significant low-density lipoprotein cholesterol (LDL-C) lowering defined as a follow up LDL-C ≥30 mg/dL lower than baseline (primary clinical outcome). Aim 2: Interview patients who received the intervention to identify barriers to success Aim 3: Assess the overall costs of the intervention and the costs per each patient who achieves significant LDL-C lowering compared to patient who received usual care.
Conditions Studied
Interventions
- BEHAVIORAL Population Health Management Intervention
Study Locations (3)
Illinois
- Near North Health Service Corporation - Chicago
- Heartland Health Outreach - Chicago
Arizona
- North Country Health Care - Flagstaff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610609
The ClinicalTrials.gov registry entry for NCT01610609 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Population Health Management Intervention is the first listed.
NCT01610609 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT01610609 about?
NCT01610609 is a clinical study titled "Reducing Disparities in Primary Prevention of Cardiovascular Disease". Cardiovascular disease (CVD) is the leading cause of disparities in years of life lost by race and low socioeconomic status. Statins have been shown to decrease the risk of cardiovascular events among individuals with high CVD risk. Yet, despite increased statin use and overall declining CVD rates, ...
What is the current status of trial NCT01610609?
This trial is currently completed. It is a NA study. The enrollment target is 646 participants. The study started on 2012-06. Estimated completion is 2014-07.
What conditions does trial NCT01610609 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Cholesterol, LDL.
What interventions are being tested in trial NCT01610609?
The interventions under investigation include: Population Health Management Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01610609?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01610609 being conducted?
This trial has 3 study locations across Arizona, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.